Kai Rejeski: The clinical impact of the new European Hematology Association The EBMT grading of immune effector cell-associated hematotoxicity

Kai Rejeski, Postdoctoral Researcher at the Gene Center, Ludwig-Maximilians-University, shared a post on X:

“Great to see this out in print in Blood Advances! Check out our study examining the clinical impact of the new European Hematology Association The EBMT grading of immune effector cell-associated hematotoxicity in a cohort of ~550 CAR T cell patients. We think that this study supports integrating the ICAHT grading system in new clinical trials evaluating CAR-T products ”

Read further.
Source: Kai Rejeski/X